Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

Lasse H Jakobsen, Fredrik Ellin, Knut B Smeland, Tove Wästerlid, Jacob H Christensen, Judit M Jørgensen, Pär L Josefsson, Andreas K Øvlisen, Harald Holte, Yngvild N Blaker, Jacob H Grauslund, Jon Bjørn, Daniel Molin, Ingemar Lagerlöf, Karin E Smedby, Katherine Colvin, Gita Thanarajasingam, Matthew J Maurer, Thomas M Habermann, Kevin W SongKatie Y Zhu, Alina S Gerrie, Chan Y Cheah, Tarec C El-Galaly

Research output: Contribution to journalJournal articleResearchpeer-review

2 Citations (Scopus)
Original languageEnglish
JournalBritish Journal of Haematology
Volume189
Issue number4
Pages (from-to)661-671
Number of pages11
ISSN0963-1860
DOIs
Publication statusPublished - May 2020

Keywords

  • Burkitt lymphoma
  • immunochemotherapy
  • prognosis
  • real-world patients
  • survival

Fingerprint Dive into the research topics of 'Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients'. Together they form a unique fingerprint.

Cite this